RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > Spotlight on Drug Risks

Spotlight on Drug Risks

Posted 01 September 2009 | By

Efforts by the US Food and Drug Administration (FDA) to strengthen risk disclosure and management have intensified, causing the pharmaceutical industry to rethink its approach to advertising and promotional labeling. This article provides an overview of the recent intensified efforts by FDA related to risk information for pharmaceutical drug products.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe